Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 27, 2021 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

-- Additional ~$19M Funding for Expanded Anthrax PEP Development Program -- BARDA Contract Now Valued at Up to ~$304M -- Development Milestones Specified for Future Procurements ...
September 23, 2021 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2021

BOSTON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that data from the NUZYRA® (omadacycline) clinical and microbiology programs are being...
September 09, 2021 08:30 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
September 01, 2021 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
August 18, 2021 16:12 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA® (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria

BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
August 09, 2021 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter -- Reported $37.9 Million in Revenue from the Delivery...
August 04, 2021 16:30 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces NUZYRA® (omadacycline) Has Been Added to the CDC Plague Guidelines for the Treatment, Pre-Exposure and Postexposure Prophylaxis of Plague

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
August 03, 2021 16:30 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
August 02, 2021 16:35 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
August 02, 2021 16:30 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021

BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right